Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 5 Issue 1

Development of a Bio analytical Assay for the Determination of Rupatadine in Human Plasma and its Clinical Applications

Pankaj Dagur1, Gourav Rakshit1, Shreya Sharma1, Ankit Aggarwal1, Krishna Kant1, Ratna Ghosh2, Suddhasatya Dey3 and Manik Ghosh1

1Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India
2Birsa Educational Institutions and Research Foundation, Khunti, Jharkhand, India
3Bengal College of Pharmaceutical Sciences and Research, Durgapur, West Bengal, India

*Corresponding Author: Manik Ghosh, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India.

Received: December 07, 2020; Published: December 22, 2020



The latest corona-virus disease (nCOVID-19) which originated in Wuhan, China, and since then has been spreading around the world is a dangerous strain of corona-virus which is a highly communicable and morbific viral infection confirmed to cause by severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2).Similarity index analysis in our study revealed that SARS-CoV-2 is related to SARS-CoV that had earlier emerged in 2002-03. The rapid transmission rates among humans and the severity of this new strain of CoV have made it a major concern worldwide. To date, the world is still lacking to approve clinically effective drugs or vaccines against COVID-19. Though clinical trials for some antiviral drugs have been tested to treat/prevent COVID-19, results are not satisfactory. As part of our response to the ongoing COVID-19 pandemic across the world, we in our current review have summarized and comparatively analyzed the sequence similarity of SARS-CoV-2 and previously identified other strains i.e. SARS-CoV(2002-03) and MERS-CoV (2012-14). We have also discussed the new potential approaches that could be effective for treating the symptoms related to nCOVID-19 to cope with this viral outbreak across the globe.

Keywords: COVID-19; SARS; MERS; Pathogenesis; Symptoms; Treatment Approaches



  1. Rothan HA and Byrareddy SN. “The epidemiology and pathogenesis of corona-virus disease (COVID-19) outbreak”. Journal of Autoimmunity 109 (2020): 102433.
  2. “Corona-virus disease”. World Health Organization 2019 (2020): 2633.
  3. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel corona-virus: implications for virus origins and receptor binding”. Lancet10224 (2020): 565-574.
  4. Chafekar A and Fielding BC. “MERS-CoV: Understanding the latest human corona-virus threat”. Viruses 2 (2018): 93.
  5. Sigrist CJ., et al. “A potential role for integrins in host cell entry by SARS-CoV-2”. Antiviral Research 177 (2020): 104759.
  6. Guo J., et al. “Corona-virus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Corona-virus 2 Infection”. Journal of the American Heart Association 7 (2020): e016219.
  7. Centres for Disease Control and Prevention. 2019 Novel Corona-virus (2020).
  8. Hui DS., et al. “SARS: clinical features and diagnosis”. (2003): 20-24.
  9. Cheng H., et al. “Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19”. Journal of Medical Virology7 (2020): 726-730.
  10. Belouzard S., et al. “Mechanisms of corona-virus cell entry mediated by the viral spike protein”. Viruses 6 (2012): 1011-1033.
  11. Jose RJ and Manuel A. “COVID-19 cytokine storm: the interplay between inflammation and coagulation”. Lancet Respiratory Medicine (2019): 2019-2020.
  12. Ye Q., et al. “Cytokine Storm in COVID-19 and Treatment”. Journal of Infection (2020).
  13. Wang W., et al. “Updated understanding of the outbreak of 2019 novel corona-virus (2019-nCoV) in Wuhan, China”. Journal of Medical Virology4 (2020): 441-447.
  14. White M. “SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19”. Gut 69 (2020): 2-3.
  15. “Ministry of Health and Family Welfare” (2020).
  16. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel corona-virus (2019-nCoV) in vitro”. Cell Research3 (2020): 269-271.
  17. Lancet IT and Wang Y. “Remdesivir for COVID-19 : challenges of underpowered studies”. Lancet 20 (2020): 31022-31023.
  18. Ekins S and Madrid PB. “Tilorone, a broad-spectrum antiviral for emerging viruses”. Antimicrobe Agents and Chemotherapy5 (2020): 1-7.
  19. Duan K., et al. “Effectiveness of convalescent plasma therapy in severe COVID-19 patients”. PNAS (2020): 1-7.
  20. , et al. “Therapeutic options for the treatment of 2019 ‑ novel corona-virus : An evidence based approach”. Indian Journal of Pharmacology 52.1 (2020): 1-5.
  21. Chen W. “The SARS-CoV-2 Vaccine Pipeline: an Overview”. Current Tropical Medicine Reports (2020): 1-4.
  22. Glowacka I., et al. “Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Corona-virus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response”. Journal of Virology9 (2011): 4122-4134.
  23. Uno Y. “Camostat mesilate therapy for COVID-19”. Internal Emergency Medicine (2020): 10-11.
  24. Tellis MB., et al. “Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-Specific SARS-CoV-2 Structurally Conserved Main Protease”. Journal of Biomolecular Structure and Dynamics (2020): 1-16.
  25. Ace H., et al. “Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Article Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using”. Cell (2020): 1-9.
  26. Huang J., et al. “Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase , Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19”. Journal of Clinical Medicine 2 (2020): 1-23.
  27. Gao J and Hu S. “Update on use of chloroquine/hydroxychloroquine to treat corona-virus disease 2019 (COVID-19)”. Bioscience in Trends2 (2020): 156-158.
  28. Stower H. “Lopinavir-ritonavir in severe COVID-19”. Nature Medicine4 (2020): 465.
  29. Branchett WJ. “Regulatory cytokine function in the respiratory tract”. Mucosal Immunology (2019).
  30. Stebbing J., et al. “COVID-19 : combining antiviral and anti-inflammatory treatments”. Lancet Infection Disease19 (2020): 2019-2020.
  31. Centers for Disease Control and Prevention. 2019 Novel Corona-virus (2020).
  32. World Health Organization. “Novel Corona-virus (2019-nCoV) advice for the public” (2020).


Citation: Manik Ghosh., et al. “A Brief Understanding of COVID-19: Pathogenesis, Symptoms and Possible Treatment Approaches”. Acta Scientific Pharmaceutical Sciences 5.1 (2021): 70-79.

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is February 05, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US